Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Nemours Foundation has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units, indicating that each pending matter occupies a separate examination setting.
DEAL, DAVID R is the identified busiest examiner. Counsel should manage the portfolio through matter-specific response planning while maintaining consistency across the biotechnology work.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEAL, DAVID R | 1 | 83.5% | +12.1% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| DAVIS, RUTH A | 1 | 60.9% | +31.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18368737 | COMPOSITIONS AND METHODS OF TREATMENT OF TUMORS EXPRESSING PUTATIVE ZIKA VIRUS RECEPTOR PROTEINS | YU, DAVID TUYANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265076 | ELEVATION OF GLYCOSAMINOGLYCANS IN SUBJECTS WITHOUT MUCOPOLYSACCHARIDOSIS | DAVIS, RUTH A | 15d overdue |
| 18792224 | KINK-REDUCING IV LINES AND EXTENSION SETS | DEAL, DAVID R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265076 | ELEVATION OF GLYCOSAMINOGLYCANS IN SUBJECTS WITHOUT MUCOPOLYSACCHARIDOSIS | DAVIS, RUTH A | 15d overdue |
| 18792224 | KINK-REDUCING IV LINES AND EXTENSION SETS | DEAL, DAVID R | — |
| Art Unit | Apps |
|---|---|
| 3753 | 1 |
| 1635 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18792224 | KINK-REDUCING IV LINES AND EXTENSION SETS | DEAL, DAVID R | 3753 | §102§103 | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18368737 | COMPOSITIONS AND METHODS OF TREATMENT OF TUMORS EXPRESSING PUTATIVE ZIKA VIRUS RECEPTOR PROTEINS | YU, DAVID TUYANG | 1635 | §103DP | Final Rejection | — | Pending | Sep 15, 2023 |
| 18265076 | ELEVATION OF GLYCOSAMINOGLYCANS IN SUBJECTS WITHOUT MUCOPOLYSACCHARIDOSIS | DAVIS, RUTH A | 1699 | §101§112Other | Final Rejection | 15d overdue | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Nemours Foundation has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
David R Deal has the most, with 1 of The Nemours Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
